Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Truist Securities Maintains Buy on NextCure, Lowers Price Target to $15

Truist Securities Maintains Buy on NextCure, Lowers Price Target to $15

Truist Securities analyst Asthika Goonewardene maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $19 to $15.

byBenzinga Newsdesk

August 23, 2022

1 minute read

Truist Securities analyst Asthika Goonewardene maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $19 to $15.

Analyst Ratings

Analyst Ratings for Array Technologies

By Benzinga Insights

September 6, 12:00 PM

Within the last quarter, Array Technologies (NASDAQ:ARRY) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

ARRY

Why Fear Level Among US Investors Is Decreasing

By Lisa Levin

March 17, 2:13 AM

The CNN Money Fear and Greed index showed some easing in the fear level among US investors on Thursday.

AQN

Fusion Fuel Inks JV Deal With Electus For Green Hydrogen Project In California

By Shivani Kumaresan

November 28, 7:49 AM

Fusion Fuel Green PLC (NASDAQ:HTOO) has entered into a joint venture agreement with Electus Energy to develop a large-scale green hydrogen…

HTOO

WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake

By Vandana Singh

May 19, 10:51 AM

An advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the

AZN

Truist Securities Maintains Buy on NextCure, Lowers Price Target to $15

Related Posts

Analyst Ratings for Array Technologies

Why Fear Level Among US Investors Is Decreasing

Fusion Fuel Inks JV Deal With Electus For Green Hydrogen Project In California

WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake